CAS 53-86-1 MFCD00057095-Indomethacin 吲哚美辛 -LabNovo

Indomethacin 吲哚美辛

CAS 53-86-1 MFCD00057095

化学结构图

SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1

化学属性

Mol. Formula	C19H16ClNO4
Mol. Weight	357.79
Melting Point	155-162 °C
TSCA	Yes
Appearance	白色或微黄色结晶性粉末。熔点158-162℃。溶于丙酮，略溶于乙醇、氯仿、乙醚，几乎不溶于水。无味，几乎无臭。
Solubility	ethanol: 50 mg/mL, clear, yellow-green
Density	1.32

别名和识别编码

Chemical Name	Indomethacin
CAS Number	53-86-1
Synonym	Indomethacin {Chemicalbook} 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indole-3-aceticaci 1-(4-氯苯甲酰基 1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-乙酸 1-(P 1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure 1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indole-acetic acid 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-ac {} {uni_hamburg} 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic {} {} {JNK} 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid {} {} {} {TRC} 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic Acid {} {} {} {} {uni_hamburg} 1-(4-Chlorbenzoyl)-5-methoxy-2-methyl-1H-indol-3-essigsäure {} {} {} {} {} {Chemicalbook} 1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOLE-3-ACETIC ACID {} {} {} {} {} {} {SNA} 1- {} {} {} {} {} {} {} {Chemicalbook} (1-p-chlorobenzoyl-5-methoxy-2-methylindol-3-yl)aceticacid {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {C
MDL Number	MFCD00057095
Beilstein Registry Number	22(5)5,239
EC Number	200-186-5
Merck Number	4968
PubChem Substance ID	3715
Reaxys-RN	497341
Chemical Name Translation	吲哚美辛
Wiswesser Line Notation	T56 BNJ BVR CG& C1 D1VQ GO1
LabNetwork Molecule ID	LN00222621
InChI	InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
Canonical SMILES	COC1=CC=C(N(C(C2=CC=C(Cl)C=C2)=O)C(C)=C3CC(O)=O)C3=C1

信息真实价格透明资金保障专业采购外包团队在线服务

品牌质保精细包装现货库存一流品牌服务

产品应用

环加氧酶(COX) 抑制剂,选择性地抑制COX-1；阻断前列腺索的生物合成。
医药上抗炎，解热作用明显，主要用于对水杨酸类药物不易耐受或疗效不显著的风湿性并节炎、强直性光脊椎炎、骨关节炎等。

安全信息

GHS Symbol

Personal Protective Equipment Eyeshields, Faceshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Precautionary statements

P201 Obtain special instructions before use. 使用前获取专门指示。
P202 Do not handle until all safety precautions have been read and understood. 已阅读并理解所有的安全预防措施之前，切勿操作。
P260 Do not breathe dust/fume/gas/mist/vapours/spray. 不要吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
P261 Avoid breathing dust/fume/gas/mist/vapours/spray. 避免吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
P264 Wash hands thoroughly after handling. 处理后要彻底洗净双手。
P270 Do not eat, drink or smoke when using this product. 使用本产品时不要吃东西，喝水或吸烟。
P271 Use only outdoors or in a well-ventilated area.? 只能在室外或通风良好的地方使用。
P272 Contaminated work clothing should not be allowed out of the workplace. 污染的工作服不得带出工作场所。
P273 Avoid release to the environment. 避免释放到环境中。
P280 Wear protective gloves/protective clothing/eye protection/face protection. 戴防护手套/防护服/眼睛的保护物/面部保护物。
P281 Use personal protective equipment as required. 使用所需的个人防护装备。
P301+P310
P301+P310+P330
P302+P352
P304+P340
P305+P351+P338
P307+P311
P308+P313
P310 Immediately call a POISON CENTER or doctor/physician. 立即呼救解毒中心或医生/医师。
P312 Call a POISON CENTER or doctor/physician if you feel unwell. 如果你感觉不适，呼叫解毒中心或医生/医师。
P314 Get medical advice/attention if you feel unwell. 获取医疗咨询/就医，如果你觉得不舒服
P321 Specific treatment (see … on this label). 具体治疗（见本标签上的）。
P330 Rinse mouth. 漱口
P333+P313
P363 Wash contaminated clothing before reuse. 被污染的衣服洗净后方可重新使用。
P403+P233
P405 Store locked up. 上锁保管。
P501 Dispose of contents/container to..… 处理内容物/容器.....

Hazard statements

H300 Fatal if swallowed 吞食致命
H301 Toxic if swallowed 吞食有毒
H317 May cause an allergic skin reaction 可能导致皮肤过敏
H318 Causes serious eye damage 严重伤害眼睛
H335 May cause respiratory irritation 可能导致呼吸道刺激
H336 May cause drowsiness or dizziness 肯能导致嗜睡或头晕
H360 May damage fertility or the unborn child 可能对生育能力或未出生婴儿造成伤害
H370 Causes damage to organs 导致器官损伤
H373 May causes damage to organs through prolonged or repeated exposure 长期或频繁接触可能会损伤器官
H413 Maycauselonglastingharmfuleffectstoaquaticlife 可能对水生生物造成长期持续有害影响。

WGK Germany3

Signal word

RTECSNL3500000

Safety Statements

S28 After contact with skin, wash immediately with plenty of ... (to be specified by the manufacturer) 皮肤接触后，立即用大量…（由生产厂家指定）冲洗；
S45 In case of accident or if you feel unwell seek medical advice immediately (show the label where possible) 发生事故时或感觉不适时，立即求医（可能时出示标签）；
S20 When using do not eat or drink 使用时，不得进食，饮水；
S36/37 Wear suitable protective clothing and gloves 穿戴适当的防护服和手套；

Packing GroupI

UN Number UN 2811 6.1/PG 1 2811

Risk Statements

R68 Possible risk of irreversible effects 可能有不可挽回的作用的危险
R28 Very toxic if swallowed 吞咽极毒

Hazard Codes T+

Storage condition 2-8°C, protect from light {LY} 2-8°C, protect from light Light Sensitive {} {LY} 2-8°C, protect from light {} {} {LY} 2-8°C, protect from light {} {} {} {LY} 2-8°C, protect from light {} {} {} {} {LY} 2-8°C, protect from light {} {} {} {} {} {LY} 2-8°C, protect from light {} {} {} {} {} {} {LY} 2-8°C, protect from light {} {} {} {} {} {} {} {LY} 2-8°C, protect from light {} {} {} {} {} {} {} {} {LY} 2-8°C, protect from light {} {} {} {} {} {} {} {} {} {LY} 2-8°C, protect from light

Hazard Class6.1

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 644 mg/kg/92W-C
TOXIC EFFECTS :
   Tumorigenic - neoplastic by RTECS criteria
   Skin and Appendages - tumors
REFERENCE :
   CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House,
   Southfield Road, Eynsham, Oxford OX8 1JJ, UK)  V.1-    1980-
   Volume(issue)/page/year: 16,1493,1995

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 21 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   ARZNAD Arzneimittel-Forschung. Drug Research.  (Editio Cantor Verlag,
   Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.)  V.1-    1951-
   Volume(issue)/page/year: 31,655,1981

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intramuscular
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 18200 ug/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   ARZNAD Arzneimittel-Forschung. Drug Research.  (Editio Cantor Verlag,
   Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.)  V.1-    1951-
   Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOS

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 2420 ug/kg
TOXIC EFFECTS :
   Gastrointestinal - ulceration or bleeding from stomach
REFERENCE :
   ARZNAD Arzneimittel-Forschung. Drug Research.  (Editio Cantor Verlag,
   Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.)  V.1-    1951-
   Volume(issue)/page/year: 25,1526,1975

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 12 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   OYYAA2 Oyo Yakuri.  Pharmacometrics.  (Oyo Yakuri Kenkyukai, CPO Box 180,
   Sendai 980-91, Japan) V.1-    1967-  Volume(issue)/page/year: 2,70,1968

TYPE OF TEST            : LD50 -

TYPE OF TEST            : Mutation in microorganisms
TEST SYSTEM             : Bacteria - Salmonella typhimurium
DOSE/DURATION           : 100 ug/disc
REFERENCE :
   JNUDAT Journal of Nihon University School of Dentistry.  (Nihon University
   School of Dentistry, 1-8-13 Surugadai, Kanda, Chiyoda-ku, Tokyo, 101, Japan)
    V.1-    1958-  Volume(issue)/page/year: 34,183,1992

TYPE OF TEST            : Micronucleus test
ROUTE OF EXPOSURE       : Intraperitoneal
TEST SYSTEM             : Rodent - mouse
DOSE/DURATION           : 72 mg/kg/24H
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 188,343,1987

TYPE OF TEST            : Mutation test systems - not otherwise specified
TEST SYSTEM             : Rodent - rat Cells - not otherwise specified
DOSE/DURATION           : 10 mg/L
REFERENCE :
   REXMAS Research in Experimental Medicine.  (Springer-Verlag, Heidelberger
   Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.)  V.157-    1972-
   Volume(issue)/page/year: 189,173,1989

TYPE OF TEST            : Dominant lethal test
ROUTE OF EXPOSURE       : Oral
TEST SYSTEM             : Rodent - ra

TYPE OF TEST            : Sperm Morphology
ROUTE OF EXPOSURE       : Oral
TEST SYSTEM             : Rodent - mouse
DOSE/DURATION           : 60 mg/kg/5D (Continuous)
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 188,343,1987

TYPE OF TEST            : Micronucleus test
ROUTE OF EXPOSURE       : Oral
TEST SYSTEM             : Rodent - mouse
DOSE/DURATION           : 72 mg/kg/24H
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 188,343,1987

TYPE OF TEST

{ha

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE                    : 525 mg/kg
SEX/DURATION            : female 16-32 week(s) after conception
TOXIC EFFECTS :
   Reproductive - Maternal Effects - parturition
   Reproductive - Maternal Effects - other effects
   Reproductive - Specific Developmental Abnormalities - urogenital system
REFERENCE :
   AJMGDA American Journal of Medical Genetics.  (John Wiley & Sons Ltd., 605
   Third Ave., New York, NY 10158)  V.1-    1977-  Volume(issue)/page/year:
   39,252,1991

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE                    : 12 mg/kg
SEX/DURATION            : fema

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intramuscular
SPECIES OBSERVED        : Primate - monkey
DOSE                    : 6 mg/kg
SEX/DURATION            : female 2 day(s) pre-mating
TOXIC EFFECTS :
   Reproductive - Fertility - other measures of fertility
REFERENCE :
   CCPTAY Contraception.  (Geron-X, Inc., POB 1108, Los Altos, CA 94022)  V.1-
   1970-  Volume(issue)/page/year: 27,505,1983

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Unreported
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 3 mg/kg
SEX/DURATION            : female 20 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Specific Developmental Abnormalities - cardiovascular
   (circulatory) system
REFERENCE :
   TJADAB Teratology, The International Journal of Abnormal Development. (Alan
   R. Liss, Inc., 41 E. 11th St., New York, NY 10003)  V.1-    1968-
   Volume(issue)/page/year: 30(1),20A,1984

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Parenteral
SPEC

其他信息

TCI Shanghai:吲哚美辛 Indomethacin,>;98.0%(LC)(T)(53-86-1)
毒性分级:剧毒
消炎镇痛药:吲哚美辛又称消炎痛，是一种作用较强的非皮质激素类的消炎解热和镇痛药，通过抑制环氧酶减少前列腺素(PG)合成，制止炎症组织痛觉神经冲动的形成，抑制炎性反应，包括抑制白细胞的趋化性及溶酶体酶的释放等，从而产生解热、镇痛及消炎作用。吲哚美辛的消炎、解热作用很强，其抗炎作用比保泰松强84倍，比氢化可的松也强，与糖皮质激素、阿司匹林、保泰松联合使用，可减少它们的用量、毒性及副作用，提高疗效；其次是解热作用，为氨基比林的10倍；镇痛作用较弱，只对炎性疼痛有明显镇痛作用，但对炎性疼痛的效果好于保泰松、安乃近和水杨酸类。临床主要用于对水杨酸类药物不易耐受，或疗效不明显的急、慢性风湿性或类风湿性关节炎、强直性脊柱炎、滑囊炎、腱鞘炎、关节囊炎、骨关节炎、急性痛风及癌性疼痛等。近年来研究人员尝试将吲哚美辛用于胆绞痛、痛经、偏头痛、肾小球肾炎、多尿、沙门菌性胃肠炎、体位性低血压、巴特综合征等，均有较好疗效。还可用于治疗眼科色素膜炎、角膜炎、巩膜炎、青光眼以及癌症引起的发热或其他难以控制的发热。皮肤科用于红斑狼疮、白塞综合征、硬皮病、结节性红斑、带状疱疹、关节型银屑病等。外用治疗湿疹、过敏性皮炎、光感性皮炎、局部疼痛。
不良反应:吲
灭火剂:泡沫、雾状水、砂土、二氧化碳
可燃性危险特性:明火可燃; 高热分解有毒氯化物和氮氧化物气体
MS
药动学:口服给药吸收迅速而完全，4h可吸收给药量的90%以上，食物或服用含铝及镁的制酸药可稍使吸收减慢，血浆蛋白结合率约为99%。口服25mg后达峰时间为1～4h，血药峰浓度(Cmax)为1.4μg/ml，50mg时Cmax为2.8μg/ml;半衰期(t1/2) 平均为4.5h，早产儿明显延长。少量吲哚美辛可透过血-脑屏障。并可透过胎盘。本品在肝脏代谢为去甲基化物和去氯苯甲酰化物，又可水解为吲哚美辛重新吸收再循环。60%从肾脏排泄，其中10%～20%以原形排出;部分随粪便排出。33% 从胆汁排泄，其中1.5%为原形;在乳汁中也有排出(每日可达0.5～2.0mg)。本品不能被透析清除。
图谱信息:吲哚美辛(53-86-1)核磁图( 1 HNMR) 吲哚美辛(53-86-1)核磁图( 13 CNMR) 吲哚美辛(53-86-1)质谱(MS) 吲哚美辛(53-86-1)红外图谱(IR1) 吲哚美辛(53-86-1)红外图谱(IR2)
用法与用量:1.抗风湿：成人用量：口服：初量每次25～50mg，每日2～4次，饭时饭后立即服。如耐受好，每日用量可每周递增25～50mg，1日最大量不应超过200mg。关节炎患者如有持续性夜间疼痛或晨僵现象，可将全天量100mg于睡前给予。 2.抗痛风：口服：初量1次100mg，继之50mg，每日3次，直至疼痛缓解，然后尽快逐渐减量，直至停药。 3.退热：成人用量：口服：每次25～50mg，每日3～4次;直肠给药：每次50mg，每日50～100mg。小儿用量：口服：每次0.5～1mg/kg，每日3次。
急性毒性:口服- 大鼠 LD50 2.42 毫克/ 公斤; 口服- 小鼠 LD50: 11.84 毫克/公斤
方法一:对氨基苯甲
上游原料:对甲氧基
Alfa Aesar:吲哚美辛,98% Indomethacin, 98%(53-86-1)
{Chemica
不良反应:吲哚美辛的不良反应的发生率相当高，常见的不良反应如下： ①恶心、呕吐、腹痛、腹泻、纳差，严重者可出现溃疡并引起出血和穿孔等。饭后即服可减少发生率。 ②常见有头痛、头晕、乏力，偶有惊厥、精神错乱、晕厥等。应注意适时停药。 ③皮肤瘙痒、红斑、荨麻疹以及少有的哮喘发作、呼吸困难甚至呼吸、循环的抑制。 ④造血系统的抑制如粒细胞减少、再生障碍性贫血、血小板减少等。虽
用途三:环加氧酶(COX) 抑制剂,选择性地抑制COX-1；阻断前列腺索的生物合成。医药上抗炎，解热作用明显，主要用于对水杨酸类药物不易耐受或疗效不显著的风湿性并节炎、强直性光脊椎炎、骨关节炎等。

Indomethacin 吲哚美辛

CAS 53-86-1 MFCD00057095

化学结构图

化学属性

别名和识别编码

分类

产品应用

相关文献及参考

安全信息

其他信息

系列性分类

相关产品推荐

Products Indices

Mailings

Contact

链接

搜索结果

化学结构图

化学属性

别名和识别编码

分类

产品应用

相关文献及参考

安全信息

其他信息

系列性分类

相关产品推荐

Products Indices

Mailings

Contact

链接